The FDA and biotech company Genentech have revised the safety warnings for the psoriasis drug Raptiva. The revisions include a new warning about a type of anemia called immune-mediated hemolytic ...

Genentech and FDA announced the withdrawal of psoriasis treatment Raptiva due to a risk of progressive multifocal leukoencephalopathy (PML), a rare and deadly viral brain infection. The agency added a ...

WASHINGTON (CNN)-- The government is warning that taking the psoriasis drug Raptiva could result in serious brain infection and even death. The Food and Drug Administration cited three confirmed cases ...

Genentech Inc. and Xoma Ltd. said Raptiva, their drug for the skin disorder psoriasis, failed in a study to ease symptoms of a related form of arthritis. Shares of both companies fell, with Xoma down ...

WASHINGTON, April 9 (UPI) -- The U.S. Food and Drug Administration says Genentech Inc. is withdrawing the psoriasis drug Raptiva and it will no longer be available in the United States. The FDA said ...

GENEVA, Switzerland, February 19 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Medicines Agency (EMEA) has recommended to the European ...

Roche has raised $16 billion from the bond market to fund its takeover of Genentech. It will probably need to pay $40-45 billion to get the company. Roche has about $4.9 billion in cash on its balance ...

A medical advisory panel Tuesday recommended Food and Drug Administration approval of Raptiva, bringing Genentech Inc. closer to entering the coveted market for psoriasis drugs. The expert committee ...

WASHINGTON, Feb 19 (Reuters) - Sales of Merck KGaA's psoriasis drug Raptiva should be suspended in light of serious brain infections confirmed in three patients, European authorities recommended on ...

South San Francisco, CA, and Berkeley, CA – Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA™ (efalizumab) has been approved by the U.S. Food and Drug ...